{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969772",
  "id": "02969772",
  "pages": 37,
  "price_sensitive": true,
  "date": "20250716",
  "time": "1040",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250716/pdf/06lv9wd986qnc6.pdf",
  "summary": "Here\u2019s the material information extracted from the ASX announcement, tailored for trading and capital markets decisions:\n\n### **Capital Raising Announcement**  \n- **Structure**: Placement (+ Share Purchase Plan)  \n  - **Placement**: A$22.5m (68.2m new shares)  \n  - **SPP**: A$15m (max A$100k per shareholder)  \n- **Pricing**: A$0.33/share (22.4% discount to last close).  \n- **Attaching Options**: 3 options per 4 new shares (exercise price A$0.43, expiry 30 Mar 2026).  \n- **Piggyback Options**: 1 option per attaching option exercised (exercise price A$0.86, expiry 30 Jun 2028).  \n- **Key Dates**:  \n  - Record date for SPP: 15 Jul 2025  \n  - SPP open/close: 24 Jul \u2013 18 Aug 2025  \n  - EGM for approvals: ~20 Aug 2025.  \n- **Post-raise pro forma cash**: A$64m (funding runway to 2H 2026).  \n- **Potential additional funding**: A$36.7m if all options exercised.  \n\n### **Clinical & Commercial Highlights**  \n- **Azer-cel (allogeneic CAR-T therapy)**:  \n  - **Phase 1b results**: 75% ORR, 55% CR in refractory DLBCL (12 patients).  \n  - **Durability**: Best response >450 days ongoing.  \n  - **Regulatory pathway**: FDA Fast Track designation; End-of-Phase 1b meeting targeted for Q4 2025.  \n  - **Market opportunity**: >US$2bn in niche lymphomas.  \n- **Catalysts**: Additional Ph1b data (Q3/Q4 2025), pivotal trial initiation (2026).  \n\n### **Other Programs**  \n- **CF33 (oncolytic virus) & onCARlytics**: Phase 1 trials ongoing (minimal data disclosed).  \n\n### **Risks**  \n- Clinical, regulatory, and funding risks highlighted (no new material risks beyond standard biotech cautions).  \n\n**Omitted**: Background on management, non-core pipeline details, and disclaimer boilerplate.",
  "usage": {
    "prompt_tokens": 12673,
    "completion_tokens": 491,
    "total_tokens": 13164,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-16T01:42:33.556468"
}